Galectin Therapeutics Inc (GALT) Stock: A SWOT Analysis

Company’s 36-month beta value is 0.69.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for GALT is 42.38M, and currently, short sellers hold a 5.30% ratio of that floaft. The average trading volume of GALT on April 17, 2024 was 130.33K shares.

GALT) stock’s latest price update

The stock price of Galectin Therapeutics Inc (NASDAQ: GALT) has dropped by -13.04 compared to previous close of 3.91. Despite this, the company has seen a fall of -13.71% in its stock price over the last five trading days. InvestorPlace reported 2024-04-05 that Galectin Therapeutics (NASDAQ: GALT ) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents.

GALT’s Market Performance

GALT’s stock has fallen by -13.71% in the past week, with a monthly rise of 65.05% and a quarterly rise of 86.81%. The volatility ratio for the week is 12.24% while the volatility levels for the last 30 days are 10.53% for Galectin Therapeutics Inc The simple moving average for the past 20 days is 15.39% for GALT’s stock, with a 77.94% simple moving average for the past 200 days.

Analysts’ Opinion of GALT

Many brokerage firms have already submitted their reports for GALT stocks, with H.C. Wainwright repeating the rating for GALT by listing it as a “Buy.” The predicted price for GALT in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on August 13, 2020 of the previous year 2020.

B. Riley FBR, on the other hand, stated in their research note that they expect to see GALT reach a price target of $11. The rating they have provided for GALT stocks is “Buy” according to the report published on February 13th, 2019.

H.C. Wainwright gave a rating of “Buy” to GALT, setting the target price at $10 in the report published on December 07th of the previous year.

GALT Trading at 48.18% from the 50-Day Moving Average

After a stumble in the market that brought GALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.34% of loss for the given period.

Volatility was left at 10.53%, however, over the last 30 days, the volatility rate increased by 12.24%, as shares surge +58.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +93.18% upper at present.

During the last 5 trading sessions, GALT fell by -13.71%, which changed the moving average for the period of 200-days by +144.60% in comparison to the 20-day moving average, which settled at $3.01. In addition, Galectin Therapeutics Inc saw 104.82% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at GALT starting from ELDRED KARY, who purchase 500 shares at the price of $1.79 back on Jan 16 ’24. After this action, ELDRED KARY now owns 49,313 shares of Galectin Therapeutics Inc, valued at $893 using the latest closing price.

ELDRED KARY, the Director of Galectin Therapeutics Inc, purchase 1,598 shares at $1.79 during a trade that took place back on Jul 19 ’23, which means that ELDRED KARY is holding 48,813 shares at $2,854 based on the most recent closing price.

Stock Fundamentals for GALT

The total capital return value is set at -3.04.

Based on Galectin Therapeutics Inc (GALT), the company’s capital structure generated 6.22 points at debt to capital in total, while cash flow to debt ratio is standing at -0.46. The debt to equity ratio resting at -1.19. The interest coverage ratio of the stock is -13.64.

Currently, EBITDA for the company is -38.04 million with net debt to EBITDA at -1.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.

Conclusion

In a nutshell, Galectin Therapeutics Inc (GALT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts